» Articles » PMID: 33261666

Clinical Comparisons Between Previously Diagnosed SLE and Newly Diagnosed SLE by Kidney Biopsy

Overview
Publisher Biomed Central
Date 2020 Dec 2
PMID 33261666
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lupus nephritis is a type of major organ involvement in systemic lupus erythematosus (SLE) patients that leads to higher rates of morbidity and mortality and may present initially in 28% of SLE patients. However, there are limited data available on clinical differences or predictors for biopsy-proven lupus nephritis in established versus newly diagnosed SLE cases.

Methods: Adult patients undergoing kidney biopsy for the first time with a diagnosis of lupus nephritis were eligible for inclusion. Patients were categorized into two groups: those with previously diagnosed SLE and those with newly diagnosed SLE by kidney biopsy. Factors associated with newly diagnosed SLE were determined using logistic regression analysis.

Results: There were 68 patients diagnosed with lupus nephritis by kidney biopsy. Of those, 31 cases (45.58%) were newly diagnosed. The newly diagnosed SLE group was significantly older (36.87 vs 30.95 years) and had a lower proportion of females (74.19% vs 91.89%) than the previously diagnosed group. A new-onset hypertension was the only factor independently associated with newly diagnosed SLE by kidney biopsy. The adjusted odds ratio (95% CI) was 5.152 (1.046, 25.363).

Conclusions: Nearly half of the biopsy-proven lupus nephritis cases in this study were patients with newly diagnosed SLE. Patients with previously diagnosed SLE and newly diagnosed SLE by kidney biopsy had clinical differences.

Citing Articles

[ granule inhibits podocyte autophagy in systemic lupus erythematosus: a network pharmacology and clinical study].

Chen J, Huang C, Li M Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(3):465-473.

PMID: 38597437 PMC: 11006693. DOI: 10.12122/j.issn.1673-4254.2024.03.07.


Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.

Anders H, Furie R, Malvar A, Zhao M, Hiromura K, Weinmann-Menke J Nephrol Dial Transplant. 2023; 38(12):2733-2742.

PMID: 37463054 PMC: 10689192. DOI: 10.1093/ndt/gfad167.


Endocapillary hypercellularity levels are associated with early complete remission in children with class IV lupus nephritis as the initial presentation of SLE.

Li C, Han Y, Zhang L, Chen Z, Jin M, Sun S BMC Nephrol. 2022; 23(1):296.

PMID: 36008770 PMC: 9413905. DOI: 10.1186/s12882-022-02921-5.

References
1.
Almaani S, Meara A, Rovin B . Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2016; 12(5):825-835. PMC: 5477208. DOI: 10.2215/CJN.05780616. View

2.
Kasitanon N, Magder L, Petri M . Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore). 2006; 85(3):147-156. DOI: 10.1097/01.md.0000224709.70133.f7. View

3.
Aulakh R, Singh S . Strategies for minimizing corticosteroid toxicity: a review. Indian J Pediatr. 2008; 75(10):1067-73. DOI: 10.1007/s12098-008-0211-6. View

4.
Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5):299-308. DOI: 10.1097/01.md.0000091181.93122.55. View

5.
Tan T, Fang H, Magder L, Petri M . Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol. 2012; 39(4):759-69. PMC: 3605704. DOI: 10.3899/jrheum.111061. View